---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-044164"
form_type: "8-K"
ticker: "RGEN"
cik: "0000730272"
company_name: "REPLIGEN CORP"
filed_at: "2023-02-22T23:59:59+00:00"
generated_at: "2026-06-19T05:42:30.492644+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Repligen Q4 revenue flat YoY at $186.8M; guides 2023 revenue down 5% to $760-800M

## Summary
- Q4 GAAP EPS $0.85 (up from $0.50 YoY); adjusted EPS $0.68 (down from $0.81).
- Full year 2022 revenue $801.5M (+20% YoY); base organic growth 39%.
- 2023 guidance: revenue $760-800M (down from 2022 due to $100-110M COVID decline); base organic growth 12-16%.
- Gross margin declines: Q4 GAAP 51.4% (down 460 bps), full year 56.9%; 2023 guided 52.5-53.5%.
- Launched 10 new products in 2022; cell/gene therapy revenue grew >50%; signed 2 partnerships.

## SEC filing metadata
- accession: 0001193125-23-044164
- form_type: 8-K
- ticker: RGEN
- cik: 0000730272
- company_name: REPLIGEN CORP
- filed_at: 2023-02-22T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/730272/000119312523044164/0001193125-23-044164-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/730272/000119312523044164/d457202d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-044164
- JSON: https://secwatch.observer/filing/0001193125-23-044164.json
- Plain text: https://secwatch.observer/filing/0001193125-23-044164.txt

## Key facts
- Earnings Releases
  REPLIGEN CORP reported financial results for the fourth quarter and year end December 31, 2022.
  - Period: the fourth quarter and year end December 31, 2022
  - Result: reported results
  source text: On February 22, 2023, Repligen Corporation announced its financial results for the fourth quarter and year end December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/730272/000119312523044164/0001193125-23-044164-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.